Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Julie B. Kessel, MD
Advertisement
Articles by Julie B. Kessel, MD
Advertisement
Latest Updated Articles
- Clinical and Cost Outcomes of Buprenorphine Treatment in a Commercial Benefit Plan Population
Published: February 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
5
